Welcome to our dedicated page for DR REDDYS LABORATORIES SEC filings (Ticker: RDY), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on DR REDDYS LABORATORIES's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into DR REDDYS LABORATORIES's regulatory disclosures and financial reporting.
Dr. Reddy’s Laboratories Limited reports that the United States Food & Drug Administration has completed a Pre-License Inspection at its biologics manufacturing facility in Bachupally, Hyderabad. The inspection, conducted from June 16 to June 25, 2026, resulted in a Form 483 with seven observations.
The company states it will address these observations within the stipulated timeline. This update follows earlier inspections and related disclosures made to stock exchanges on October 12, 2023 and September 13, 2025, and is provided for information of investors and exchanges.
Dr. Reddy’s Laboratories Limited has scheduled a Board meeting for July 22, 2026 to consider the company’s unaudited standalone and consolidated financial results for the quarter ending June 30, 2026. The company also announced that its trading window for dealing in its securities will be closed from June 24, 2026 to July 24, 2026, in line with insider trading regulations.
Dr. Reddy’s Laboratories Limited submitted a Form 6-K providing an intimation to multiple stock exchanges about shareholder communications. The company enclosed copies of newspaper advertisements titled “Notice of the 42nd Annual General Meeting to be held through video conference, record date and final dividend information,” published in Business Standard and Nava Telangana. The same communication was also emailed to all shareholders, ensuring broad circulation of details about the upcoming annual general meeting and related dividend information.
Dr. Reddy’s Laboratories Limited reported a routine employee stock option exercise. The company allotted 6,730 equity shares of Re.1 each on June 19, 2026 to eligible employees under its 2002 Employee Stock Option Scheme and 2007 Employees ADR Stock Option Scheme.
The allotment covers 2,455 shares at an exercise price of Re.1, 2,000 shares at Rs. 562.80, and 2,275 shares at Rs. 735.80. After this issue, total issued shares are 83,46,76,800 and total issued share capital is Rs. 83,46,76,800, with paid-up capital of 83,46,75,800 equity shares of Re.1 each.
Dr. Reddy’s Laboratories has announced the first-to-market U.S. launch of Bosutinib Tablets 400mg, a generic equivalent of Bosulif, expanding its oncology portfolio and focus on affordable cancer care. The product is a first-to-file generic and is eligible for 180 days of generic drug exclusivity for the 400mg strength in the United States.
Dr. Reddy’s holds exclusive marketing rights in the U.S., while MSN Laboratories developed and manufactures the product. The Bosulif 400mg brand recorded approximately $253.8 million in U.S. sales for the 12 months ended April 2026, highlighting the commercial potential of this oncology therapy launch.
Dr. Reddy’s Laboratories Limited filed a Form 6-K to share its schedule of analyst and institutional investor meetings. The company’s management plans to participate in an Investec investor conference in London from June 16, 2026 to June 17, 2026, with in-person group meetings scheduled between 09:00 and 17:00 BST. The company notes that this schedule may change depending on circumstances for either the investors or the company.
Dr. Reddy’s Laboratories Limited reported the allotment of 12,100 equity shares of Re.1 each on June 5, 2026 to eligible employees who exercised stock options. The shares were issued under the Dr. Reddy’s Employees Stock Option Scheme, 2002 and the Employees ADR Stock Option Scheme, 2007.
After this issue, total issued shares stand at 83,46,70,070 and total issued share capital is Rs. 83,46,70,070. The new shares carry no premium, rank pari passu with existing equity shares, and are of the same ISIN INE089A01031.
Dr. Reddy’s Laboratories Limited filed a Form 6-K to inform markets that its management will participate in upcoming investor conferences. The company plans a group investor meet organized by ICICI Securities in Mumbai on June 9, 2026 from 10:00 to 17:00 IST, and another group meeting organized by Macquarie in Hyderabad on June 10, 2026 from 12:00 to 13:00 IST. The company notes that these schedules may change due to exigencies on the part of investors or the company.
Dr. Reddy’s Laboratories Limited has notified exchanges that its management will participate in an investor conference. The meeting is scheduled for June 5, 2026, organized by Bank of America in Hyderabad as an in-person group meeting from 08:00 to 09:00 IST. The company notes that this schedule may change if needed by either the investors or the company. This update is provided as an information-only disclosure on the company’s investor relations activities.